WuXi Biologics (Cayman) Inc. announced that with effect from March 31, 2024, Dr. Zhou has retired from his roles as Chief Technology Officer and President of Global Biologics Development and Operations of the Company, and has been re-designated as a non-executive Director and Honorary President of Global Biologics Development and Operations and Senior Advisor to Chief Executive Officer to continue to support the Company's development. Following the Re-designation, Dr. Zhou will remain as a member of the strategy committee of the Board. The biographical details of Dr. Zhou are as follows: Dr. Weichang Zhou, aged 60, was appointed as an executive Director, Chief Technology Officer and President of Global Biologics Development and Operations of the Company in May 2016, November 2016 and October 2022, respectively until his retirement as senior management of the Company in March 2024.

He was primarily responsible for overseeing the development and manufacturing of biologics. He was also responsible for several global operational functions such as Global Information and Technology (GIT), Global Automation Integrated Service (GAIS), and Environment and Health and Safety (EHS) from October 2022 to March 2024. He joined the Group in December 2012 as the vice president, and has had responsibilities for the management of biologics development and manufacturing function teams at increased scales.

Since December 2020, Dr. Zhou has been serving as a director of WuXi XDC Cayman Inc. and was re-designated as a non-executive director of XDC in June 2023, where he is primarily responsible for providing guidance on corporate strategy and governance. Prior to joining the Group, Dr. Zhou served as a senior director of Genzyme Corporation (now part of Sanofi) from March 2008 to December 2012, and was responsible for commercial cell culture process development. From October 2002 to February 2008, Dr. Zhou served as a senior director of PDL BioPharma Inc. and was responsible for process sciences and engineering functions.

From May 1994 to October 2002, Dr. Zhou served as up to an associate director of Merck & Co. Inc. and was responsible for fermentation and cell culture process development. Dr. Zhou obtained a Ph.D. degree in Chemical Engineering from the University of Hannover in 1989 and conducted postdoctoral research at the German Association of Chemical Engineering and Biotechnology, Swiss Federal Institute of Technology Zurich, and the University of Minnesota.

Save as disclosed above, Dr. Zhou does not, at present, nor did he in the past three years, hold any directorship in any other public companies the securities of which are listed in Hong Kong or overseas. In respect of the Re-designation, the Company has entered into a new service contract with Dr. Zhou, pursuant to which he was appointed as a non-executive Director for an initial term of three years commencing from March 31, 2024 which is terminable by either party with at least three months' written notice, subject to retirement by rotation and re-election at least once every three years at the annual general meeting of the Company in accordance with the provisions of the articles of association of the Company. Dr. Zhou is entitled to a director's remuneration of HKD 1,200,000 per annum as determined by the Board with reference to Dr. Zhou's relevant experience and qualifications, his duties and responsibilities, the prevailing market conditions and the recommendation from the remuneration committee of the Board.

Dr. Zhou does not have any relationships with any Directors or senior management or substantial shareholders or controlling shareholders of the Company.